Since the ASCO 2014 abstracts were released to the public on May 14, 2014 at 5:00pm EDT, the pre-meeting buzz in the press has been mostly about immunotherapies – specifically immunotherapies targeted against the immune checkpoint inhibitors Programmed (Cell) Death 1 (PD1) and its ligand (PDL1). The late-stage investigational PD1/PDL1 antagonists pembrolizumab/MK-3475 (Merck), nivolumab (Ono/Bristol-Myers Squibb) and MPDL3280A (Genentech/Roche) have garnered most of the pre-ASCO press and results of trials with several other early-stage PD1/PDL1 biologics, pidilizumab (Curetech), MEDI4736 (MedImmune/AstraZeneca), MSB-0010718C (Merck KGaA), will also be presented at ASCO.
But what other immunotherapies warrant our attention at ASCO 2014? Promising results from immunotherapies in early-stage clinical development from a diverse array of industry and academic sponsors and/or collaborations will be presented. Many of these therapies have already advanced into later-stage clinical trials or will be evaluated in additional trials within the next year (1). Highlighted below are the presentations from three types of immunotherapies.
Chimeric Antigen Receptor (CAR)-Engineered T Cells
Oncolytic Viruses
Antibody-Drug Conjugates
Presentations from phase I trials include:
Presentations from phase I/II and phase II trials include:
Summary table of the highlighted immunotherapies
| Drug Name | Disease | Target | Trial Phase at ASCO | Industry Developer | Abstract |
| CAR-Engineered T Cells | |||||
| CD19-targeted CAR+T cells | CLL | CD19 | I | Juno | 7020 |
| CTL019 | ALL, CLL | CD19 | I, II | Novartis | |
| PG13-CD19-H3 transduced PBL/KTE-C19 CAR | B cell lymphoma or leukemia | CD19 | I | Kite | 3079 |
| Oncolytic Viruses | |||||
| Cavatak/CVA-21 | melanoma | II | Viralytics | 3031 | |
| enadenotucirev | epithelial solid tumors | I | PsiOxus | 3103 | |
| pelareorep/Reolysin | brain tumors | I | Oncolytics | 3104 | |
| Antibody-Drug Conjugates | |||||
| DMOT4039A | pancreatic or ovarian cancers | MSLN | I | Genentech | 2529 |
| DNIB0600A | NSCLC or ovarian cancer | NaPi2b (SLC34A2) | I | Genentech | 2504 |
| DSTP3086S | prostate cancer | STEAP-1 | I | Genentech | 5024 |
| IMGN529 | NHL | CD37 | I | ImmunoGen | 8526 |
| IMGN853 | ovarian cancer or FRα positive solid tumors | FRα | I | ImmunoGen | 5571 |
| MLN0264 | gastrointestinal tumors | GCC | I | Millennium | 3546 |
| SGN-LIV1A | breast cancer | LIV-1 | I | Seattle Genetics | TPS1143 |
| IMMU-130 | colorectal cancer | CEACAM5 | I/II | Immunomedics | 3106 |
| IMMU-132 | solid tumors | Trop-2 | I/II | Immunomedics | 3032 |
| PSMA ADC | prostate cancer | PSMA | II | Progenics | 5023 |
So look past the frenzy about the anti-PD1 and anti-PDL1 biologics at ASCO 2014 and look at the presentations about other types of immunotherapies, namely CAR-engineered T cells, oncolytic viruses and antibody-drug conjugates. Some of these early-stage immunotherapies could steal the show at ASCO 2015
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topics Cell and gene therapy
Trialtrove: 医療用医薬品の臨床試験情報データベース
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
Topics Drug Development Landscape BioPharmaceutical Business Strategies
Trialtrove: 医療用医薬品の臨床試験情報データベース
Review the trends, diseases, sponsors and outcomes involved with recent patient-centric clinical trials.
Topics Clinical Trials
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
ご質問等ございましたらお気軽にご連絡下さい。
日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
Datamonitor Healthcare(データモニターヘルスケア)では主要な疾患と医薬品をカバーする市場調査レポートを収載し、定期的に更新しています。市場調査レポート1本単位の購入または疾患単位の購読契約による対象の市場調査レポートすべての閲覧が可能です。新医薬品の市場性の評価や研究開発戦略の立案にご利用ください。
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.
Pharmaprojects(ファーマプロジェクツ)は、医薬品業界で代表的な開発パイプライン(医療用医薬品候補化合物)のデータベースとして、医薬品企業をはじめとする多くのお客様にご利用いただいています。前臨床試験から上市済み医薬品まで、現在開発中の15,000の薬剤を含む68,000以上の開発パイプライン情報を収録しています。さらに、43,000以上の医薬品を網羅した35年間にわたる過去のデータベースにもアクセスできます。グローバル競争が激しくなる中、競合分析や研究開発戦略の策定に威力を発揮するデータベースです。
